Hubbry Logo
Oct-4Oct-4Main
Open search
Oct-4
Community hub
Oct-4
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Oct-4
Oct-4
Oct-4
View on Wikipedia
from Wikipedia
For the day, see October 4.
"Oct-3" redirects here. For the day, see October 3.

POU5F1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesPOU5F1, OCT3, OCT4, OTF-3, OTF3, OTF4, Oct-3, Oct-4, POU class 5 homeobox 1, Oct3/4
External IDsOMIM: 164177; MGI: 101893; HomoloGene: 8422; GeneCards: POU5F1; OMA:POU5F1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

5460

18999

Ensembl

ENSMUSG00000024406

UniProt

Q01860

P20263

RefSeq (mRNA)

NM_203289
NM_001173531
NM_001285986
NM_001285987
NM_002701

NM_001252452
NM_013633

RefSeq (protein)

NP_001239381
NP_038661

Location (UCSC)Chr 6: 31.16 – 31.18 MbChr 17: 35.82 – 35.82 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Oct-4 (octamer-binding transcription factor 4), also known as POU5F1 (POU domain, class 5, transcription factor 1), is a protein that in humans is encoded by the POU5F1 gene.[5] Oct-4 is a homeodomain transcription factor of the POU family. It is critically involved in the self-renewal of undifferentiated embryonic stem cells.[6] As such, it is frequently used as a marker for undifferentiated cells. Oct-4 expression must be closely regulated; too much or too little will cause differentiation of the cells.[7]

Octamer-binding transcription factor 4, OCT-4, is a transcription factor protein that is encoded by the POU5F1 gene and is part of the POU (Pit-Oct-Unc) family.[8] OCT-4 consists of an octamer motif, a particular DNA sequence of AGTCAAAT that binds to their target genes and activates or deactivates certain expressions. These gene expressions then lead to phenotypic changes in stem cell differentiation during the development of a mammalian embryo.[9] It plays a vital role in determining the fates of both inner mass cells and embryonic stem cells and has the ability to maintain pluripotency throughout embryonic development.[10] Recently, it has been noted that OCT-4 not only maintains pluripotency in embryonic cells but also has the ability to regulate cancer cell proliferation and can be found in various cancers such as pancreatic, lung, liver and testicular germ cell tumors in adult germ cells.[11] Another defect this gene can have is dysplastic growth in epithelial tissues which are caused by a lack of OCT-4 within the epithelial cells.[12]

Expression and function

[edit]

Oct-4 transcription factor is initially active as a maternal factor in the oocyte and remains active in embryos throughout the preimplantation period. Oct-4 expression is associated with an undifferentiated phenotype and tumors.[13] Gene knockdown of Oct-4 promotes differentiation, demonstrating a role for these factors in human embryonic stem cell self-renewal.[14] Oct-4 can form a heterodimer with Sox2, so that these two proteins bind DNA together.[15]

Mouse embryos that are Oct-4 deficient or have low expression levels of Oct-4 fail to form the inner cell mass, lose pluripotency, and differentiate into trophectoderm. Therefore, the level of Oct-4 expression in mice is vital for regulating pluripotency and early cell differentiation since one of its main functions is to keep the embryo from differentiating.

Orthologs

[edit]

Orthologs of Oct-4 in humans and other species include:

Species Entrez GeneID Chromosome Location RefSeq (mRNA) RefSeq (protein)
Mus musculus (mouse) 18999 17,17 B1; 17 19.23 cM NC_000083.4, 35114104..35118822 (Plus Strand) NM_013633.1 NP_038661.1
Homo sapiens (human) 5460 6, 6p21.31 NC_000006.10, 31246432-31240107 (Minus Strand) NM_002701.3 NP_002692.2 (full length isoform)
NP_002692.1 (N-terminal truncated isoform)
Rattus norvegicus (rat) 294562 20 NW_001084776, 650467-655015 (Minus strand) NM_001009178 NP_001009178
Danio rerio (zebrafish) 303333 21 NC_007127.1, 27995548-28000317 (Minus strand) NM_131112 NP_571187

Structure

[edit]

Oct-4 contains the following protein domains:

Domain Description Length (AA)
POU domain Found in Pit-Oct-Unc transcription factors 75
Homeodomain DNA binding domains involved in the transcriptional regulation of key eukaryotic developmental processes; may bind to DNA as monomers or as homodimers and/or heterodimers in a sequence-specific manner. 59

Implications in disease

[edit]

Oct-4 has been implicated in tumorigenesis of adult germ cells. Ectopic expression of the factor in adult mice has been found to cause the formation of dysplastic lesions of the skin and intestine. The intestinal dysplasia resulted from an increase in progenitor cell population and the upregulation of β-catenin transcription through the inhibition of cellular differentiation.[16]

Pluripotency in embryo development

[edit]

Animal model

[edit]

In 2000, Niwa et al. used conditional expression and repression in murine embryonic stem cells to determine requirements for Oct-4 in the maintenance of developmental potency.[7] Although transcriptional determination has often been considered as a binary on-off control system, they found that the precise level of Oct-4 governs 3 distinct fates of ES cells. An increase in expression of less than 2-fold causes differentiation into primitive endoderm and mesoderm. In contrast, repression of Oct-4 induces loss of pluripotency and dedifferentiation to trophectoderm. Thus, a critical amount of Oct-4 is required to sustain stem cell self-renewal, and up- or down-regulation induces divergent developmental programs. Changes to Oct-4 levels do not independently promote differentiation, but are also controlled by levels of Sox2. A decrease in Sox2 accompanies increased levels of Oct-4 to promote a mesendodermal fate, with Oct-4 actively inhibiting ectodermal differentiation. Repressed Oct-4 levels that lead to ectodermal differentiation are accompanied by an increase in Sox2, which effectively inhibits mesendodermal differentiation.[17] Niwa et al. suggested that their findings established a role for Oct-4 as a master regulator of pluripotency that controls lineage commitment and illustrated the sophistication of critical transcriptional regulators and the consequent importance of quantitative analyzes.

The transcription factors Oct-4, Sox2, and Nanog are part of a complex regulatory network, with Oct-4 and Sox2 being capable of directly regulating Nanog by binding to its promoter, and are essential for maintaining the self-renewing undifferentiated state of the inner cell mass of the blastocyst, embryonic stem cell lines[18] (which are cell lines derived from the inner cell mass), and induced pluripotent stem cells.[15] While differential up- and down-regulation of Oct-4 and Sox2 has been shown to promote differentiation, down-regulation of Nanog must occur for differentiation to proceed.[17]

Role in reprogramming

[edit]

Oct-4 is one of the transcription factors that is used to create induced pluripotent stem cells (iPSCs), together with Sox2, Klf4, and often c-Myc (OSKM) in mice,[19][20][21] demonstrating its capacity to induce an embryonic stem-cell-like state. These factors are often referred to as "Yamanaka reprogramming factors". This reprogramming effect has also been seen with the Thomson reprogramming factors, reverting human fibroblast cells to iPSCs via Oct-4, along with Sox2, Nanog, and Lin28. The use of Thomson reprogramming factors avoids the need to overexpress c-Myc, an oncogene.[22] It was later determined that only two of these four factors, namely Oct4 and Klf4, are sufficient to reprogram mouse adult neural stem cells.[23] Finally it was shown that a single factor, Oct-4 was sufficient for this transformation.[24] Moreover, while Sox2, Klf4, and cMyc could be replaced by their respective family members, Oct4's closer relatives, Oct1 and Oct6, fail to induce pluripotency, thus demonstrating the exclusiveness of Oct4 among POU transcription factors.[25] However, later it was shown that Oct4 could be completely omitted from the Yamanaka cocktail, and the remaining three factors, Sox2, Klf4, and cMyc (SKM) could generate mouse iPSCs with dramatically enhanced developmental potential.[26] This suggests that Oct4 increases the efficiency of reprogramming, but decreases the quality of resulting iPSCs. This is possibly due to a mutated OCT4 DBD cysteine residue (Cys48) that has been identified as a central reprogramming determinant.[27] The serine residue in OCT1 is mutated in the presence of the OCT4 N terminus, which conversely causes OCT4's serine (converted from cysteine) to reduce reprogramming efficiency by 60%.[27]

In embryonic stem cells

[edit]
  • In in vitro experiments of mouse embryonic stem cells, Oct-4 has often been used as a marker of stemness, as differentiated cells show reduced expression of this marker.
  • Oct3/4 can both repress and activate the promoter of Rex1. In cells that already express high level of Oct3/4, exogenously transfected Oct3/4 will lead to the repression of Rex1.[28] However, in cells that are not actively expressing Oct3/4, exogenous transfection of Oct3/4 will lead to the activation of Rex1.[28] This implies a dual regulatory ability of Oct3/4 on Rex1. At low levels of the Oct3/4 protein, the Rex1 promoter is activated, while at high levels of the Oct3/4 protein, the Rex1 promoter is repressed.
  • Oct4 contributes to the rapid cell cycle of ESCs by promoting progression through the G1 phase, specifically through transcriptional inhibition of cyclin-dependent kinase inhibitors such as p21.[29]
  • CRISPR-Cas9 knockout of the gene in human embryonic stem cells demonstrated that Oct-4 is essential for the development after fertilisation.[30]
  • Oct3/4 represses Suv39h1 expression through the activation of an antisense long non-coding RNA. Suv39h1 inhibition maintains low level of H3K9me3 in pluripotent cells limiting the formation of heterochromatin.[31]

In adult stem cells

[edit]

Several studies suggest a role for Oct-4 in sustaining self-renewal capacity of adult somatic stem cells (i.e. stem cells from epithelium, bone marrow, liver, etc.).[32] Other scientists have produced evidence to the contrary,[33] and dismiss those studies as artifacts of in vitro culture, or interpreting background noise as signal,[34] and warn about Oct-4 pseudogenes giving false detection of Oct-4 expression.[35] Oct-4 has also been implicated as a marker of cancer stem cells.[36][37] A majority of Oct4 cancer stem-like cell studies (CSC) report a positive association between expression of OCT4 and chemoresistance.[38] Chemotherapy resulting in the enrichment of CSCs showed changes in the phenotypes and increased stem cell markers of OCT4.[39] Various cancers such as lung cancer, bladder cancer, and mesothelioma cells with high OCT4 expressions showed resistance to cisplatin, general drug resistance, and tumor recurrence.[38] Breast cancer patients had tamoxifen resistance and poor clinical outcomes associated with OCT4.[40] OCT4 knock-downs increase sensitivity to cisplatin and irradiation in lung cells, retained tumorigenicity in glioma-initiating cells, and metastasis mediation in ovarian cancer.[38] In in vitro studies looking at cisplatin, knock-down of OCT4 increased their sensitivity and reduced cell proliferation.[38] Further investigation is needed due to the sparsity of stem cells within tumors and their heterogeneity.

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Oct-4

View on Grokipedia
from Grokipedia
Oct-4, also known as OCT4 or POU5F1, is a POU domain-containing that plays a central role in maintaining the pluripotency and self-renewal of embryonic s in mammals. Encoded by the Pou5f1 gene, it binds specifically to octamer DNA motifs (ATGCAAAT) and acts as a key regulator of during early embryonic development. Highly expressed in totipotent and pluripotent cells such as the of the and primordial germ cells, Oct-4 expression is rapidly downregulated upon differentiation, making it a hallmark marker of stem cell identity. Oct-4 was independently discovered in 1990 through cloning efforts that identified it as an octamer-binding protein expressed in preimplantation embryos, oocytes, and embryonic carcinoma cells. Pioneering studies by Schöler et al. demonstrated its sequence-specific DNA binding and transactivation properties, while Rosner et al. and Okamoto et al. highlighted its restricted expression pattern in undifferentiated cells, establishing it as a critical developmental regulator. Structurally, Oct-4 features a bipartite POU domain consisting of POU-specific (POU_S) and POU-homeodomain (POU_H) subdomains connected by a flexible linker, enabling cooperative interactions with partner proteins like SOX2 and NANOG to form enhanceosomes that drive pluripotency networks. In function, Oct-4 orchestrates a balance between self-renewal and lineage commitment by activating pluripotency genes such as Nanog and while repressing differentiation inducers like Cdx2 and Gata6. Its precise expression levels are vital: elevated Oct-4 promotes primitive endoderm formation, while reduced levels drive trophectoderm differentiation, underscoring its role as a dosage-sensitive gatekeeper of cell fate. Beyond development, Oct-4 is indispensable for induced pluripotency; it was identified as one of the four Yamanaka factors (along with , , and c-MYC) capable of reprogramming somatic cells into induced pluripotent s (iPSCs) in 2006, revolutionizing . Dysregulated Oct-4 expression has also been implicated in tumorigenesis, where it contributes to cancer stem cell maintenance and therapy resistance in various malignancies.

Gene and Protein

Genomic Organization and Isoforms

The , which encodes the , is located on the short arm of at position 6p21.33, spanning approximately 6 kb from genomic coordinates 31,164,337 to 31,170,682 on the reverse strand in the GRCh38.p14 assembly. The broader locus, including upstream alternative promoters for isoforms like OCT4B, extends to approximately 16 kb (31,164,337 to 31,180,731 per Ensembl GRCh38). The consists of five exons, with the coding sequence distributed across these exons, and its organization is conserved across mammalian species, including mice and rabbits, where similar exon-intron structures support equivalent transcriptional regulation. Alternative splicing and promoter usage of POU5F1 generate multiple isoforms, with OCT4A representing the full-length, canonical variant essential for pluripotency. OCT4A is transcribed from exons 1, 2b, 2d, 3, and 4, encoding a 360-amino-acid protein that includes an N-terminal transactivation domain critical for its transcriptional activity. In contrast, OCT4B isoforms arise from an alternative promoter upstream of exon 2a and lack exon 1, resulting in shorter proteins such as OCT4B-265 (265 amino acids), OCT4B-190 (190 amino acids), and OCT4B-164 (164 amino acids), which exclude the transactivation domain and exhibit reduced transcriptional potency but enhanced stability under cellular stress conditions. These OCT4B variants localize to both the nucleus and cytoplasm and are associated with stress responses rather than pluripotency maintenance, differing from OCT4A in protein half-life and regulatory interactions. Additionally, the processed pseudogene POU5F1P1 on chromosome 8q24 produces transcripts that encode a protein with 95% homology to OCT4A, potentially contributing to expression variability in certain contexts like cancer, though it lacks full functional equivalence. The intron-exon boundaries and core promoter regions of POU5F1 are highly conserved evolutionarily among mammals, reflecting shared regulatory mechanisms for , as evidenced by sequence alignments across species like , , and that preserve splicing signals and proximal promoter elements such as the CR4 region. Polymorphisms within the POU5F1 promoter and regulatory regions, including variants like those identified in resequencing studies, influence transcriptional variability and have been linked to differential expression levels in stem cells and disease states.

Protein Structure and DNA Binding

The Oct-4 protein, also known as OCT4 or POU5F1, is a 360-amino-acid transcription factor belonging to the POU family, characterized by a central bipartite POU domain responsible for DNA binding and flanked by N- and C-terminal transactivation domains. The POU domain comprises approximately 156 amino acids, divided into a POU-specific subdomain of about 75 amino acids and a POU homeodomain of roughly 59 amino acids, which together enable sequence-specific recognition of DNA targets. The N-terminal transactivation domain spans 133 amino acids, while the C-terminal domain consists of 71 amino acids, both contributing to transcriptional activation but not directly to DNA binding. Oct-4 primarily recognizes the octamer consensus motif 5'-ATGCAAAT-3' (or variants like ATTTGCAT) through its POU homeodomain, which inserts into the major groove of DNA to form specific hydrogen bonds and base contacts. In pluripotent cells, Oct-4 frequently binds cooperatively with SOX2 to composite motifs, such as the Sox-Oct element (e.g., 5'-CTTTGTTATGCAAAT-3'), where the POU-specific domain of Oct-4 interacts with the high-mobility group domain of SOX2, enhancing binding affinity and specificity by inducing DNA bending and stabilizing the complex. This cooperative mode is essential for accessing chromatinized enhancers in the pluripotency network. Recent structural studies using cryo-electron microscopy (cryo-EM) have elucidated how Oct-4 engages as a pioneer factor. In 2023, high-resolution cryo-EM structures revealed Oct-4 binding to containing LIN28B or nMATN1 DNA sequences, demonstrating partial unwrapping of nucleosomal DNA at superhelical location (SHL) +6, which facilitates access to embedded motifs without full eviction. These structures highlight Oct-4's ability to distort histone-DNA contacts, promoting opening in a sequence-specific manner. Additionally, a 2023 cryo-EM analysis of the Oct-4-LIN28B complex showed pioneer-like access to closed , with Oct-4 stabilizing multiple conformations that enhance breathing and expose binding sites. Further insights from 2022 indicate that Oct-4 binding induces flexibility by altering dynamics, as evidenced by cryo-EM and single-molecule studies showing increased DNA unwrapping probabilities and multiple binding poses, including partial detachment at entry/exit regions. These modes allow Oct-4 to scan and engage barriers effectively, underscoring its role in initiating transcriptional programs. The primary isoform OCT4A, with its full-length , serves as the dominant form for these DNA-binding activities.

Expression and Regulation

Spatial and Temporal Expression Patterns

Oct4 exhibits dynamic temporal expression patterns critical for early embryonic development. Maternal Oct4 transcripts are highly abundant in oocytes and persist through the preimplantation stages, where they play a role in maintaining totipotency during cleavage divisions. Expression peaks in the (ICM) of the , where Oct4 is essential for specifying pluripotent cells, before declining post-implantation as the epiblast differentiates during . In embryonic stem cells (ESCs) derived from the ICM, Oct4 is re-expressed at levels comparable to those in the , supporting self-renewal and pluripotency maintenance. Spatially, Oct4 expression is largely restricted to pluripotent compartments during embryogenesis, including the ICM and epiblast, with minimal detection in trophectoderm lineages. In adults, Oct4 shows low but detectable expression in germ cells, such as primordial germ cells (PGCs) in the gonads, and in select somatic tissues including the brain's niches. Isoform-specific patterns further delineate this distribution: the OCT4A isoform is predominantly confined to pluripotent cells like those in the ICM and ESCs, whereas the OCT4B isoform displays more ubiquitous expression across various types. Quantitative aspects of Oct4 expression are pivotal for lineage fate decisions, with precise dosage thresholds governing cell outcomes in mouse models. Levels exceeding approximately 150% of endogenous expression in ESCs promote differentiation toward primitive endoderm and lineages, while reductions below 50% drive loss of pluripotency and trophectoderm specification. These thresholds underscore Oct4's role as a dosage-sensitive regulator, where even modest variations alter developmental trajectories. Expression patterns are commonly assessed using quantitative PCR (qPCR) for transcript levels and for protein localization in both and models, enabling precise mapping in embryos and cultured cells.

Upstream Regulators and Post-Translational Modifications

Oct4 expression is tightly controlled by a network of upstream transcriptional regulators that form auto- and cross-regulatory loops essential for maintaining pluripotency. In embryonic stem cells (ESCs), the core pluripotency factors Nanog and bind to specific enhancer elements in the Oct4 (Pou5f1) proximal promoter and distal enhancer, promoting its transcription as part of a self-reinforcing loop. This Oct4-Sox2-Nanog triad directly activates Oct4 expression, ensuring sustained levels critical for pluripotency, as demonstrated in studies showing their co-occupancy at these sites. Conversely, during lineage commitment, repressors such as Cdx2 are upregulated in the trophectoderm lineage and directly antagonize Oct4 by competing for binding or recruiting corepressors, leading to its transcriptional silencing and prevention of ectopic pluripotency gene expression. Epigenetic modifications provide an additional layer of regulation, dynamically silencing Oct4 upon differentiation. In pluripotent cells, the Oct4 promoter exhibits bivalent chromatin marks, with active and repressive balanced to poise it for rapid activation; however, in differentiated cells, Polycomb repressive complex 2 (PRC2) deposits at the promoter, correlating with reduced transcription. DNA methylation at CpG islands within the Oct4 promoter and enhancers also reinforces silencing during differentiation, as de novo methyltransferases like Dnmt3a/b target these regions, leading to stable formation and long-term repression. These epigenetic changes are reversible in contexts, where demethylation and removal restore accessibility. Post-translational modifications (PTMs) fine-tune Oct4 protein activity, stability, and localization without altering transcription. Phosphorylation events, such as JNK-mediated modification at serine 347, negatively regulate Oct4 by reducing its transcriptional activity and promoting degradation via the ubiquitin-proteasome pathway, thereby limiting self-renewal under stress conditions. Similarly, phosphorylation within the POU homeodomain at threonine 234 and serine 235 disrupts DNA binding, inhibiting transactivation potential. SUMOylation at lysine 118 (K118 in mouse, K123 in human) has context-dependent effects; while it generally enhances stability and DNA binding in normoxia, under hypoxic conditions it promotes proteasomal degradation and reduces protein stability and activity in human cells. Ubiquitination targets Oct4 for proteasomal degradation, with disruption of these sites increasing protein half-life and enhancing pluripotency maintenance. Additionally, a 2024 study revealed redox sensitivity through cysteine 48 oxidation, which sensitizes Oct4 to oxidative stress, promoting ubiquitination and degradation while inhibiting DNA binding, thus linking cellular redox state to pluripotency dynamics. Oct4 autoregulation is mediated through feedback loops involving its own binding to the distal enhancer, in concert with and Nanog, which amplifies expression in a dose-dependent manner to prevent differentiation. This autoregulatory mechanism ensures precise Oct4 dosage, as even modest variations trigger lineage biases.

Biological Roles

In Embryonic Development and Pluripotency

Oct-4, encoded by the POU5F1 gene, plays a pivotal role in early embryonic development by maintaining the pluripotency of the (ICM) within the . In mice, Oct-4 is essential for establishing and preserving ICM identity, as its absence leads to the failure of pluripotent cells to form, resulting in embryos composed entirely of trophoblast-like cells despite reaching the blastocyst stage. This knockout phenotype underscores Oct-4's function as a gatekeeper of pluripotency, preventing premature differentiation into extraembryonic lineages during preimplantation stages. Within the pluripotency regulatory network, Oct-4 forms a core transcriptional circuit with and NANOG, where mutual activation sustains the undifferentiated state of embryonic cells. High levels of Oct-4 reinforce this self-sustaining loop by promoting the expression of pluripotency factors while suppressing differentiation genes, whereas precise dosage control is critical for lineage commitment; elevated levels promote primitive differentiation, while reduced levels drive trophectoderm fate.00825-5) This dosage-dependent mechanism ensures that embryonic cells remain poised for subsequent developmental transitions. Animal models highlight Oct-4's conserved yet nuanced roles across . In mice, Oct-4 is indispensable for ICM formation and pluripotency maintenance, as demonstrated by targeted disruptions. In humans, Oct-4 similarly supports pluripotency but operates within distinct states: the naive state, akin to the preimplantation epiblast, relies on Oct-4 alongside LIF/ signaling for ground-state maintenance, while the primed state, resembling postimplantation epiblast, integrates Oct-4 with Activin/Nodal pathways for epiblast progression. In , the ortholog Pou5f1 is required for proper embryonic patterning; maternal-zygotic mutants exhibit reduced expression of pluripotency-associated genes and fail to specify properly, leading to expanded mesodermal domains and diminished equivalents of mammalian pluripotent cell populations. The functional specificity of Oct-4 is mediated through heterodimerization with , which binds composite DNA motifs to co-regulate target genes. Oct-4/ complexes activate pluripotency genes such as Nanog by enhancing promoter accessibility and transcription, while simultaneously repressing lineage-specific genes like Gata6 to inhibit primitive endoderm differentiation.00825-5) This dual regulatory action ensures balanced critical for embryonic fate decisions.

In Embryonic and Adult Stem Cells

Oct-4, also known as OCT4 or POU5F1, serves as a critical marker of the undifferentiated state in embryonic stem cells (ESCs), where its expression levels must be precisely maintained to sustain pluripotency and prevent differentiation. In ESCs, Oct-4 regulates self-renewal by activating key pluripotency genes and repressing lineage-specific programs, ensuring the balance between proliferation and differentiation. For instance, Oct-4 directly binds to the promoter of Tcl1, an anti-apoptotic gene that enhances Akt kinase activity to promote cell survival and self-renewal in pluripotent cells. In ESCs, Oct-4 influences cell cycle progression to support rapid proliferation characteristic of the undifferentiated state. Specifically, Oct-4, in cooperation with Sox2, transcriptionally activates the miR-302 microRNA cluster, which targets and represses cyclin D1 translation, thereby shortening the G1 phase and facilitating continuous cell division. Additionally, Oct-4 contributes to heterochromatin maintenance by partnering with the histone methyltransferase Eset (Setdb1) to deposit repressive H3K9me3 marks on promoters of trophectoderm-associated genes, such as Cdx2, thereby safeguarding the pluripotent identity. Depletion of Oct-4 in ESCs disrupts this balance, leading to rapid upregulation of trophectoderm markers like Cdx2 and Hand1, and subsequent loss of pluripotency. In , Oct-4 expression is more restricted and context-dependent compared to ESCs, primarily supporting stemness in specific niches such as the . For example, Oct-4 is essential for the self-renewal of spermatogonial stem cells, where its impairs proliferation and survival without affecting somatic lineages. Expression in other adult populations, such as mesenchymal or hematopoietic stem cells, remains debated, with low or undetectable levels of functional Oct-4 reported in hematopoietic stem cells, indicating it is dispensable for their maintenance. However, Oct-4 promotes proliferation and multipotency in stem cells, where it sustains a primitive, ESC-like state during migration and differentiation potential. Isoform-specific roles further distinguish Oct-4 function across stem cell types. The OCT4A isoform predominates in ESCs, driving pluripotency through its transcriptional activity, whereas OCT4B is more variably expressed in and associated with stress responses, such as DNA damage repair, without sustaining self-renewal on its own. This differential isoform usage underscores Oct-4's adaptable contributions to stemness maintenance beyond embryonic contexts.

Reprogramming and Therapeutic Applications

Role in Induced Pluripotency

Oct-4 (also known as OCT4 or Pou5f1) serves as a core component of the Yamanaka factors, alongside , , and c-Myc, which were first demonstrated to reprogram embryonic and fibroblasts into induced pluripotent stem cells (iPSCs) in 2006.00976-7) This combination enables somatic cells to revert to a pluripotent state by reactivating the endogenous pluripotency network, though Oct-4 alone is insufficient for full as it requires cooperation with the other factors to achieve efficient conversion. Specifically, Oct-4 is essential for silencing somatic genes during the early stages of , facilitating the suppression of lineage-specific programs and the establishment of pluripotency. Mechanistically, Oct-4 functions as a pioneer transcription factor that binds directly to nucleosome-wrapped DNA, promoting chromatin opening and accessibility at pluripotency loci. This nucleosome-binding activity allows Oct-4 to initiate remodeling of closed chromatin regions, enabling subsequent recruitment of co-factors like Sox2 and activation of the endogenous pluripotency gene network, including Nanog and Sall4. Through these interactions, Oct-4 not only opens silent genomic regions but also stabilizes the pluripotency circuitry, distinguishing it from non-pioneer factors that require prior chromatin accessibility. To enhance safety and efficiency, reprogramming protocols have evolved to include non-integrating delivery methods, such as synthetic modified mRNA for the Yamanaka factors, which transiently express Oct-4 without genomic insertion risks. Recent optimizations leverage Oct-4's sensitivity, where a residue (Cys48) in its responds to to modulate activity; mutating this residue (e.g., C48S) improves efficiency by reducing inhibition under varying cellular conditions. Additionally, fusion proteins like EWS-Oct4, which replace wild-type Oct-4, have been shown to sustain self-renewal and enhance pluripotency maintenance in embryonic stem cells, potentially offering alternatives for iPSC generation. Reprogramming efficiency is influenced by Oct-4 dosage thresholds, where optimal protein levels are critical—insufficient expression fails to activate pluripotency genes, while excess can lead to aberrant activation or reduced colony formation. Species-specific differences further complicate protocols; for instance, OCT4 exhibits distinct binding preferences and reprogramming competences compared to mouse Oct4, often requiring adjusted factor combinations or higher expression levels for comparable iPSC yields.

Applications in Regenerative Medicine

(iPSC)-derived cardiomyocytes have emerged as a promising avenue for cardiac regenerative therapies, with significant advances in focusing on enhancing cellular maturity to better mimic cardiomyocytes. Techniques such as metabolic maturation media have improved structural and functional maturity, including increased organization and contractile force, enabling more effective engraftment and repair in preclinical models of . Similarly, iPSC-derived neural cells, modulated by OCT4 to promote reprogramming of neural stem cells (NSCs) into midbrain dopaminergic neurons, hold potential for treatment by replacing lost dopaminergic populations and restoring motor function in animal models. Gene editing approaches, particularly activation of endogenous neuronal genes, facilitate direct reprogramming of fibroblasts into neurons without viral integration, offering a safer alternative for generating patient-specific neural cells for transplantation. This method activates neuronal factors like NEUROD1, yielding functional induced neurons with improved efficiency and reduced genomic risks compared to traditional overexpression. A key challenge in OCT4-mediated regenerative therapies is mitigating tumorigenicity arising from aberrant OCT4 expression in residual undifferentiated cells; strategies involving precise dosage control, such as inducible promoters or partial replacement in cocktails, have shown promise in limiting formation while preserving therapeutic efficacy. Recent preclinical and early clinical advances, including 2024-2025 trials of iPSC-derived cardiomyocytes for cardiac repair, demonstrate improved safety profiles with controlled OCT4 levels during differentiation. For vascular diseases, hypoimmunogenic iPSC-derived endothelial cells enhance in ischemia models, with ongoing 2025 studies exploring variants for therapy. OCT4 plays a pivotal role in generating iPSC-derived organoids for drug testing, where its expression maintains pluripotency during initial expansion, allowing faithful recapitulation of tissue architecture for of toxicity and efficacy in . Additionally, fusion proteins like EWS-Oct4 serve as non-integrating alternatives to wild-type OCT4, enhancing self-renewal in cultures without viral vectors, thereby reducing genomic integration risks in therapeutic applications.

Pathological Implications

In Cancer Progression and Resistance

OCT4 plays a critical role in maintaining the cancer stem cell (CSC) pool across various malignancies, including and , where its expression sustains self-renewal and tumor-initiating properties. In , OCT4 co-expression with and NANOG in stem-like cells promotes multilineage potential and resistance to therapies, contributing to tumor recurrence. Similarly, in , OCT4 drives epithelial-mesenchymal transition (EMT) in CSCs, correlating with advanced tumor pathology and reduced patient survival rates. Elevated OCT4 levels in these contexts are consistently linked to poor clinical , as high expression predicts and therapy failure. Overexpression of OCT4 has been implicated in aggressive phenotypes in specific cancers. In , OCT4 upregulation enhances tumor aggressiveness, higher Gleason scores, and lineage plasticity, facilitating progression to metastatic states. In head and neck squamous cell carcinoma (HNSCC), OCT4 confers radioresistance by regulating factors like PSMC3IP and pathways, as demonstrated in studies from 2021. Gastric cancer exhibits OCT4-driven , with high expression associated with nodal involvement, advanced staging, and poorer outcomes, per 2019 analyses. In (HCC), OCT4 promotes through activation of the / signaling axis, exacerbating tumor growth as reported in 2018 research. For , particularly aggressive clear-cell variants, elevated OCT4 marks CSCs and correlates with high-grade tumors and metastatic potential, as shown in studies including a 2018 analysis of Oct4 and Nanog co-expression predicting poor . Mechanistically, OCT4 fosters cancer progression by enhancing lineage plasticity, allowing tumor cells to dedifferentiate and adapt to therapeutic pressures. It also induces EMT, promoting invasion and dissemination while upregulating ABC transporters that efflux chemotherapeutic agents, thereby conferring multidrug resistance in CSCs. The OCT4B isoform specifically responds to cellular stresses like genotoxic damage and hypoxia, supporting anchorage-independent growth and survival in harsh tumor microenvironments. Recent studies (as of 2025) further implicate OCT4 in shaping the by promoting remodeling, epithelial-mesenchymal transition, metabolic adaptations, , and immune suppression, enhancing overall tumor progression. Therapeutically, targeting OCT4 shows promise in sensitizing cancers to treatment. Knockdown of OCT4 via reduces invasion and proliferation in models like pancreatic and by inhibiting pathways such as AKT and enhancing chemosensitivity to agents like . In resistant and cancers, OCT4 inhibition disrupts CSC maintenance, suggesting its utility as a and therapeutic target to overcome resistance.

In Non-Cancerous Diseases

OCT4 dysregulation has been implicated in various developmental disorders, particularly those affecting development and leading to . In mouse models, conditional knockout of Oct4 (encoded by Pou5f1) results in of primordial germ cells (PGCs) between embryonic days 9.5 and 10.5, leading to a significant reduction in PGC numbers—up to 70% by day 10.5—and severe postnatal depletion. This manifests as germ cell aplasia, with adult males exhibiting 30–100% germ-cell-free seminiferous tubules and females showing 25–100 times fewer primordial follicles, ultimately causing sterility or impaired . In humans, while direct mutations are rare due to Oct4's essential role, ectopic or dysregulated POU5F1 expression in the male germ lineage disrupts spermatogonial differentiation, contributing to spermatogenic failure and phenotypes akin to germ cell aplasia. Furthermore, regulatory variants in POU5F1 have been associated with congenital anomalies, such as heart malformations; low-frequency functional variants increase the risk of congenital heart disease by altering enhancer activity and during cardiogenesis. Dysregulated POU5F1 expression is also observed in dysgenetic gonads, where abnormal OCT4 patterns correlate with gonadal developmental defects and conditions. In degenerative diseases, aberrant OCT4 upregulation contributes to pathological tissue remodeling. Post-myocardial infarction (MI), OCT4 expression in non-myocyte cells, including cardiac fibroblasts, mediates partial reprogramming toward cardiomyocyte-like states, potentially aiding repair. In vascular contexts, OCT4-mediated reprogramming of endothelial or valvular cells induces inflammation and transdifferentiation, leading to calcification and fibrotic lesions in aortic valves—a process observed in both mouse models and human samples where OCT4+ cells originate from embryonic lineages and drive disease progression. For neurodegeneration, iPSC-derived motor neurons from amyotrophic lateral sclerosis (ALS) patients exhibit aberrant OCT4 persistence, with expression exceeding 100 times the interquartile range in some cultures compared to controls, potentially contributing to cellular stress, impaired differentiation, and heightened vulnerability to degeneration. OCT4 implications extend to other non-cancerous pathologies, including autoimmune conditions and vascular diseases. Genetic polymorphisms in POU5F1 are linked to psoriasis vulgaris, an autoimmune disorder, where variants influence non-pluripotent cell functions and exacerbate inflammatory responses in skin tissues. In autoimmune settings, OCT4 dysregulation may promote exhaustion, as seen in hematopoietic or mesenchymal stem cells where altered pluripotency networks lead to reduced regenerative capacity and chronic inflammation. Recent 2024 studies highlight OCT4's role in vascular diseases through endothelial ; partial activation of OCT4 (via OSK factors) in endothelial cells reverses hypertension-induced dysfunction in models by improving vascular compliance and reducing stiffness, though aberrant sustained expression risks pathological endothelial-to-mesenchymal transition. Modulating OCT4 holds therapeutic potential for non-cancerous disease modeling and treatment. In disease modeling, OCT4 is a core factor in reprogramming patient fibroblasts to iPSCs, enabling generation of disease-specific cell types; for instance, iPSCs from patient fibroblasts yield motor neurons that recapitulate TDP-43 and mitochondrial dysfunction, facilitating drug screening without ethical concerns. This approach extends to other conditions, such as vascular diseases, where OCT4-modulated iPSC-derived endothelial cells model and test strategies for repair.

Evolutionary Conservation

Mammalian Orthologs

The Oct-4 orthologs in mammals, encoded by the POU5F1 gene, display a high degree of sequence conservation, with approximately 85% overall identity between and proteins, particularly in the POU DNA-binding domain. This conservation extends to their critical functions in maintaining pluripotency within the (ICM) of the . In mice, homozygous knockout of the Oct4 gene results in embryonic lethality around implantation, as the ICM cells fail to proliferate and instead differentiate into trophectoderm, highlighting Oct-4's indispensable in ICM specification. Similarly, OCT4 is essential for ICM formation and pluripotency, with disruptions leading to comparable defects in early embryogenesis models. Orthologs in other mammals, such as bovine and , exhibit similarly high sequence conservation with and OCT4 (approximately 90% identity for bovine-), including comparable isoform structures that support pluripotency networks. In bovine embryos, OCT4 maintains NANOG-positive pluripotency in the epiblast, akin to but distinct from development, where it is required for both pluripotency and lineage commitment. Pou5f1 shares over 95% identity with Oct4 and drives similar ICM functions in embryonic stem cells. The (Ornithorhynchus anatinus) Pou5f1 ortholog illustrates early mammalian evolutionary features, showing functional activity consistent with evolving roles in early differentiation, a process more specialized in therian mammals. Unlike higher mammals, platypus Pou5f1 lacks a key enhancer promoter region for autoregulation, suggesting this regulatory evolution occurred after the monotreme-therian divergence. Functional conservation is evidenced by cross-species complementation assays, where OCT4 effectively rescues pluripotency and self-renewal in Oct4-null embryonic stem cells, restoring their ability to form teratomas and contribute to chimeras. This interchangeability underscores shared molecular mechanisms despite differences. Subtle variations exist in non-coding regions, such as promoter elements, which influence expression dynamics. For instance, OCT4 promoters support expression in the primed pluripotent state of embryonic stem cells, characterized by delayed X-chromosome inactivation and epiblast-like features, differing from the naive state regulated by Oct4 promoters. These differences arise from evolutionary in upstream regulatory sequences while preserving core .

Non-Mammalian Orthologs

Orthologs of the mammalian OCT4 gene (POU5F1) are found across non-mammalian vertebrates, particularly in jawed vertebrates (gnathostomes), where the POU5 family expanded through events. In teleost fish, which underwent a whole-genome duplication, two paralogous genes, Pou5f1 and Pou5f3, emerged, contrasting with the single POU5F1 in tetrapods. For instance, in (Danio rerio), pou5f1 (also known as pou2 or spg) is expressed in the blastoderm margin during early embryogenesis and plays a critical role in movements and specification. Similarly, in medaka (Oryzias latipes), the orthologous Oloct4 gene is a single-copy Pou5f1 homolog expressed in early embryos and germ stem cells, essential for blastula formation and the derivation of pluripotent cell lines. The evolutionary origin of POU5 functions in supporting pluripotency traces back to the gnathostome lineage, prior to the teleost-specific duplication, as evidenced by phylogenetic analyses of sequences from chondrichthyans (e.g., catsharks) and sarcopterygians (e.g., ). In non-mammalian vertebrates, these orthologs exhibit broader roles beyond strict pluripotency maintenance, extending to and patterning. In Xenopus laevis, the homologs XLPOU91 (also called Xoct4 or Pou5f3.1) and Oct25 (Pou5f3.2) regulate transitions between and , suppressing premature differentiation during and coordinating specification. In , pou5f1 contributes to midbrain-hindbrain boundary formation, development via regulation of pax2a, and posterior , highlighting divergent functions in tissue patterning. Functional conservation is demonstrated through comparative assays where non-mammalian POU5 orthologs partially rescue pluripotency in embryonic stem cells (ESCs). For example, Pou5f3 shows limited rescue capacity compared to mammalian OCT4, while medaka Pou5f1 supports naïve pluripotency, and XLPOU91 effectively maintains ESC self-renewal, underscoring an ancestral pluripotency-supporting role that has diversified in lower vertebrates. These findings indicate that while POU5 orthologs retain core transcriptional mechanisms for multipotency, their expanded involvement in developmental processes reflects adaptations post-gnathostome divergence.

References

  1. https://doi.org/10.1038/344435a0
  2. https://doi.org/10.1038/345686a0
  3. https://stemcellres.biomedcentral.com/articles/10.1186/scrt39
  4. https://doi.org/10.1016/0092-8674(90)90597-8
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4163606/
  6. https://doi.org/10.1038/78099
  7. https://doi.org/10.1016/j.cell.2006.07.024
  8. https://academic.oup.com/carcin/article/26/2/495/2476063
  9. https://www.ncbi.nlm.nih.gov/gene/5460
  10. https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204531
  11. https://www.omim.org/entry/164177
  12. https://pubmed.ncbi.nlm.nih.gov/25895477/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2962909/
  14. https://pubmed.ncbi.nlm.nih.gov/18949397/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2751759/
  16. https://bmcgenomdata.biomedcentral.com/articles/10.1186/1471-2156-9-15
  17. https://www.sinobiological.com/resource/oct4
  18. https://www.uniprot.org/uniprotkb/Q01860/entry
  19. https://www.science.org/doi/10.1126/science.abb0074
  20. https://www.nature.com/articles/s41586-023-06112-6
  21. https://www.sciencedirect.com/science/article/pii/S1097276523004124
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC9928048/
  23. https://academic.oup.com/nar/article/50/18/10311/6702469
  24. https://cellregeneration.springeropen.com/articles/10.1186/2045-9769-3-7
  25. https://www.sciencedirect.com/science/article/pii/S2045976917300226
  26. https://pubmed.ncbi.nlm.nih.gov/18787205/
  27. https://pubmed.ncbi.nlm.nih.gov/10742100/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5064760/
  29. https://aacrjournals.org/cancerres/article/72/19/4963/577264/Chemotherapeutic-Sensitivity-of-Testicular-Germ
  30. https://www.sciencedirect.com/science/article/pii/S0092867400817699
  31. https://pubmed.ncbi.nlm.nih.gov/9814708/
  32. https://www.pnas.org/doi/10.1073/pnas.1319738111
  33. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001083
  34. https://aacrjournals.org/cancerres/article/68/16/6533/540864/Octamer-4-Small-Interfering-RNA-Results-in-Cancer
  35. https://pubmed.ncbi.nlm.nih.gov/18710938/
  36. https://doi.org/10.1006/dbio.2000.9713
  37. https://pubmed.ncbi.nlm.nih.gov/18719224/
  38. https://www.sciencedirect.com/science/article/pii/S1934590907000859
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC9525453/
  40. https://stemcellsjournals.onlinelibrary.wiley.com/doi/pdf/10.1634/stemcells.2008-0530
  41. https://www.nature.com/articles/s41598-020-68850-1
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC7611526/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6607707/
  44. https://genesdev.cshlp.org/content/38/7-8/308.full
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC12008092/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC10686568/
  47. https://www.science.org/doi/10.1126/sciadv.aaz7364
  48. https://www.mdpi.com/1422-0067/26/15/7248
  49. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019926
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC11073076/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3967018
  52. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1627149/full
  53. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04554-5
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC10932280/
  55. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163606/
  56. https://www.nature.com/articles/s41388-021-01842-1
  57. https://jenci.springeropen.com/articles/10.1186/s43046-019-0005-0
  58. https://www.spandidos-publications.com/10.3892/or.2018.6491
  59. https://www.nature.com/articles/s41598-018-19592-x
  60. https://pubmed.ncbi.nlm.nih.gov/40229384/
  61. https://www.embopress.org/doi/full/10.1038/sj.embor.7400279
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC5003728/
  63. https://www.nature.com/articles/srep15860
  64. https://academic.oup.com/humrep/article/19/6/1338/2356652
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC5720736/
  66. https://www.science.org/doi/10.1126/sciadv.abf7910
  67. https://www.sciencedirect.com/science/article/pii/S089662732300034X
  68. https://doi.org/10.1016/j.jdermsci.2007.01.003
  69. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.124.324909
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4772428/
  71. https://www.nature.com/articles/s41467-022-32481-z
  72. https://academic.oup.com/biolreprod/article/60/5/1093/2740846
  73. https://pubmed.ncbi.nlm.nih.gov/11309664/
  74. https://www.pnas.org/doi/10.1073/pnas.1718833115
  75. https://pubmed.ncbi.nlm.nih.gov/19021737/
  76. https://www.nature.com/articles/nmeth.2632
  77. https://www.embopress.org/doi/10.1038/msb.2010.9
  78. https://pubmed.ncbi.nlm.nih.gov/25142379/
  79. https://anatomypubs.onlinelibrary.wiley.com/doi/full/10.1002/dvdy.22727
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC9492771/
  81. https://www.embopress.org/doi/10.1038/sj.emboj.7601238
  82. https://www.sciencedirect.com/science/article/pii/S2667290124000342
  83. https://bmcbiol.biomedcentral.com/articles/10.1186/1741-7007-11-56
Add your contribution
Related Hubs
User Avatar
No comments yet.